By: Geraldus Sigap
Uterine myomas, commonly known as fibroids, are non-cancerous growths that develop in or on the uterus. These benign tumors can cause a range of symptoms, including heavy menstrual bleeding, pelvic pain, and frequent urination, affecting a woman’s quality of life. Despite being a widespread condition affecting up to 80% of women by age 50, many are unaware of the innovative treatment options available today. One such groundbreaking treatment is High-Intensity Focused Ultrasound (HIFU), a non-invasive technique that is changing the landscape of fibroid management and offering new hope to women worldwide.
Historically, treatment for uterine fibroids often involved invasive surgical procedures such as hysterectomy (removal of the uterus) or myomectomy (removal of fibroids). These procedures, while effective, require significant recovery time and can impact a woman’s fertility and overall health. Enter HIFU—a revolutionary treatment that targets fibroids without the need for incisions or long recovery periods. HIFU uses focused ultrasound waves to generate heat and destroy fibroid tissue, providing relief from symptoms with minimal impact on the surrounding healthy tissue.
High-Intensity Focused Ultrasound works by directing focused ultrasound waves to the fibroid tissue, causing a rise in temperature that leads to the destruction of the fibroid cells. The procedure is guided by real-time imaging, allowing precise targeting of the fibroid while sparing adjacent healthy tissue. This accuracy not only increases the effectiveness of the treatment but also reduces the risk of complications, making it a safer alternative to traditional surgery.
Another significant advantage of HIFU is its potential for fertility preservation. Traditional surgical methods, such as myomectomy, can pose risks of uterine rupture and miscarriage in subsequent pregnancies. In contrast, HIFU maintains uterine integrity, offering a safer option for women who wish to retain their fertility. Moreover, HIFU has been associated with fewer complications and improved clinical outcomes compared to robotic or laparoscopic surgeries, making it an appealing choice for many patients. These benefits, coupled with the convenience of outpatient treatment, make HIFU a highly effective and patient-friendly approach to managing uterine myomas.
However, not all women with fibroids are suitable candidates for HIFU. The treatment’s effectiveness depends on factors such as the size, number, and location of the fibroids. A thorough evaluation by a healthcare provider is essential to determine the suitability of HIFU for each patient. The decision to use HIFU is made based on a comprehensive assessment of the patient’s medical history, symptoms, and treatment goals.
Women considering HIFU should discuss the potential benefits and risks with their healthcare provider to make an informed decision. It is important to have realistic expectations and understand that while HIFU can significantly alleviate symptoms, it may not completely eliminate all fibroids. Ongoing monitoring and follow-up care are crucial to ensure the best outcomes.
At Abdi Waluyo Hospital, we offer state-of-the-art HIFU facilities for treating uterine myomas, providing the latest and most effective treatments with minimal recovery time. Our experienced team of specialists tailors personalized care plans to meet each patient’s unique needs, ensuring a modern and patient-centered approach to managing fibroids. Patients benefit from outpatient treatments, advanced technology, and a supportive environment, allowing them to find relief from fibroid symptoms while maintaining their quality of life.
Resources
- Tsai MC, Chang LT, Tam KW. Comparison of High-Intensity Focused Ultrasound and Conventional Surgery for Patients with Uterine Myomas: A Systematic Review and Meta-Analysis. J Minim Invasive Gynecol. 2021 Oct;28(10):1712-1724.
- Jindal S, Jung J, Lee K, Chern B. High-intensity Focused Ultrasound for the Treatment of Fibroids: A Single-center Experience in Singapore. Gynecol Minim Invasive Ther. 2023 Feb 9;12(1):15-25